MedPath

12 week, multi-center, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of YD-106AS on Osteoarthritis

Not Applicable
Recruiting
Conditions
Diseases of the musculo-skeletal system and connective tissue
Registration Number
KCT0002349
Lead Sponsor
Hallym University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

1)Male and female aged between 40 years and 75 years
2) Subject with 30 mm or greater on VAS(Visual Analogue Scale)
3) Subject with Kellgren and Lawrence grade I or II on knee or hip joint
4) Subject who signed an informed consent form prior to the study

Exclusion Criteria

1) Subject with other than degenerative arthritis determined by investigator
2)Subject whose joint space is less than 2mm
3) Subject with moderate arthritis accompanied by bone spurs around joint, irregular articular surface, chondrogenesis, and bone cyst
4) Subject with clinically significant cardiovascular, immunization, infective, or neoplastic diseases
5) Subject being treated for gastritis or gastric ulcer
6) Subject with uncontrolled hypertension (over 160/100mmHg measured at screening)
7) Subject with uncontrolled diabetes mellitus (more than 180mg/dl of fasting glucose measured at screening)
8) Subject with TSH = 0.1 µIU/ml or = 10 µIU/ml
9) Subject with AST(GOT) and ALT(GPT) = 3 times the upper limit of normal
10) Subject with Creatinine = 2 times the upper limit of normal
11) Subject who is pregnant or planning to pregnant within 3 months
12) Subject administered medication or health functional foods related to arthritis within 1 week of screening
13) Subject administered medicinal herbs or foods containing of main components of Perilla frutescens and Atractylodes macrocephala Koidzumi within 1 week of screening
14) Subject with severe mental illness
15) Subject planning to participate in the other clinical trial
16) Subject participated in any clinical trial within 3 month
17) Inappropriate subject decided by the investigator

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survey VAS;Korean - Western Ontario McMaster Universities Osteoarthritis (K-WOMAC) ;Korean-Short Form Health Survey 36(KSF-36);improvement of patients and investigator ;Inflammation of blood
Secondary Outcome Measures
NameTimeMethod
Adverse Reactions, Clinical Laboratory, electrocardiogram ;Clinical Laboratory ;electrocardiogram ;Vital Sign(Pulse, Blood Pressure), Weight
© Copyright 2025. All Rights Reserved by MedPath